Back to Search
Start Over
Modeling adaptive therapy in non-muscle invasive bladder cancer
- Publication Year :
- 2019
- Publisher :
- Cold Spring Harbor Laboratory, 2019.
-
Abstract
- Bladder cancer is the 9th most commonly diagnosed cancer. Nearly half of patients with early stage bladder cancer treated with the immune-stimulating agent BCG have disease recurrence, while 13% progress to invasive bladder cancer. Here we explored the potential of tumor mutational heterogeneity and the role of pro- and anti-inflammatory cytokines to identify different subtypes of bladder cancer that may predict therapeutic response to BCG. Further, we used mathematical modeling of dosing strategies to infer tumor response to varying doses and time schedules f BCG administration. As a proof-of-concept, present adaptive therapy scheduling of BCG as a viable strategy to control tumor size and minimize recurrence.
- Subjects :
- Oncology
0303 health sciences
medicine.medical_specialty
Bladder cancer
Tumor size
business.industry
Therapeutic treatment
Cancer
medicine.disease
Tumor heterogeneity
3. Good health
03 medical and health sciences
0302 clinical medicine
Text mining
030220 oncology & carcinogenesis
Internal medicine
medicine
business
Non muscle invasive
030304 developmental biology
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....c44afcd7d4fd62c50525fa7eb0eaccbb
- Full Text :
- https://doi.org/10.1101/826438